Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: A single center experience

C. Castagnola, E. P. Alessandrino, M. Lunghi, P. Bernasconi, M. Della Porta, S. Mangiacavalli, A. Colombo, A. Corso, G. Pagnucco, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Several trials have suggested that intensive post-remission therapy may prolong the duration of complete remission (CR) in acute myeloid leukemia (AML). The purpose of this study was to evaluate the feasibility and the efficacy of high-dose cytarabine (HiDAC) consolidation chemotherapy followed by high-dose therapy and autologous infusion of peripheral blood progenitor cells (PBPC) mobilized by G-CSF in adult patients with AML in first CR. Fifteen consecutive AML patients underwent HiDAC consolidation chemotherapy, used as a method of in vivo purging, followed by G-CSF for the purpose of autologous PBPC collection. Eleven patients collected a median of 6.9×10 8/kg peripheral blood mononuclear cells (MNC) (range 2.9-23) and a median of 6.67×10 6/kg CD34+ cells (range 1.8-33.5) with a median of two aphereses (range 1-3). Two patients did not mobilize and two obtained an inadequate number of progenitor cells. The 11 patients with adequate collections received myeloablative chemotherapy followed by the infusion of PBPC. The median number of days to recover neutrophils and platelets was 12 and 13, respectively. After a median follow-up of 28.7 months (range 17.2-43.4), five out of 11 patients who underwent PBPC transplantation are still in CR, five have died in first relapse and one is alive in CR after relapse treated with salvage therapy and second PBPC infusion. These results demonstrate that HiDAC consolidation chemotherapy followed by autologous PBPC transplantation is a feasible procedure with minimal toxicity. Randomized studies should be performed to evaluate whether this form of consolidation may produce a significant improvement in leukemia-free survival.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalAnnals of Hematology
Volume80
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Blood Cells
Stem Cells
Consolidation Chemotherapy
Granulocyte Colony-Stimulating Factor
Therapeutics
Recurrence
Salvage Therapy
Blood Component Removal
Cytarabine
Leukemia
Neutrophils
Blood Platelets
Drug Therapy
Survival

Keywords

  • AML
  • Autologous transplantation
  • Peripheral blood progenitor cells

ASJC Scopus subject areas

  • Hematology

Cite this

Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia : A single center experience. / Castagnola, C.; Alessandrino, E. P.; Lunghi, M.; Bernasconi, P.; Della Porta, M.; Mangiacavalli, S.; Colombo, A.; Corso, A.; Pagnucco, G.; Lazzarino, M.; Bernasconi, C.

In: Annals of Hematology, Vol. 80, No. 5, 2001, p. 267-271.

Research output: Contribution to journalArticle

@article{0be9404e7eae4168b60e3f6cdfa4c5a0,
title = "Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: A single center experience",
abstract = "Several trials have suggested that intensive post-remission therapy may prolong the duration of complete remission (CR) in acute myeloid leukemia (AML). The purpose of this study was to evaluate the feasibility and the efficacy of high-dose cytarabine (HiDAC) consolidation chemotherapy followed by high-dose therapy and autologous infusion of peripheral blood progenitor cells (PBPC) mobilized by G-CSF in adult patients with AML in first CR. Fifteen consecutive AML patients underwent HiDAC consolidation chemotherapy, used as a method of in vivo purging, followed by G-CSF for the purpose of autologous PBPC collection. Eleven patients collected a median of 6.9×10 8/kg peripheral blood mononuclear cells (MNC) (range 2.9-23) and a median of 6.67×10 6/kg CD34+ cells (range 1.8-33.5) with a median of two aphereses (range 1-3). Two patients did not mobilize and two obtained an inadequate number of progenitor cells. The 11 patients with adequate collections received myeloablative chemotherapy followed by the infusion of PBPC. The median number of days to recover neutrophils and platelets was 12 and 13, respectively. After a median follow-up of 28.7 months (range 17.2-43.4), five out of 11 patients who underwent PBPC transplantation are still in CR, five have died in first relapse and one is alive in CR after relapse treated with salvage therapy and second PBPC infusion. These results demonstrate that HiDAC consolidation chemotherapy followed by autologous PBPC transplantation is a feasible procedure with minimal toxicity. Randomized studies should be performed to evaluate whether this form of consolidation may produce a significant improvement in leukemia-free survival.",
keywords = "AML, Autologous transplantation, Peripheral blood progenitor cells",
author = "C. Castagnola and Alessandrino, {E. P.} and M. Lunghi and P. Bernasconi and {Della Porta}, M. and S. Mangiacavalli and A. Colombo and A. Corso and G. Pagnucco and M. Lazzarino and C. Bernasconi",
year = "2001",
doi = "10.1007/s002770000277",
language = "English",
volume = "80",
pages = "267--271",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia

T2 - A single center experience

AU - Castagnola, C.

AU - Alessandrino, E. P.

AU - Lunghi, M.

AU - Bernasconi, P.

AU - Della Porta, M.

AU - Mangiacavalli, S.

AU - Colombo, A.

AU - Corso, A.

AU - Pagnucco, G.

AU - Lazzarino, M.

AU - Bernasconi, C.

PY - 2001

Y1 - 2001

N2 - Several trials have suggested that intensive post-remission therapy may prolong the duration of complete remission (CR) in acute myeloid leukemia (AML). The purpose of this study was to evaluate the feasibility and the efficacy of high-dose cytarabine (HiDAC) consolidation chemotherapy followed by high-dose therapy and autologous infusion of peripheral blood progenitor cells (PBPC) mobilized by G-CSF in adult patients with AML in first CR. Fifteen consecutive AML patients underwent HiDAC consolidation chemotherapy, used as a method of in vivo purging, followed by G-CSF for the purpose of autologous PBPC collection. Eleven patients collected a median of 6.9×10 8/kg peripheral blood mononuclear cells (MNC) (range 2.9-23) and a median of 6.67×10 6/kg CD34+ cells (range 1.8-33.5) with a median of two aphereses (range 1-3). Two patients did not mobilize and two obtained an inadequate number of progenitor cells. The 11 patients with adequate collections received myeloablative chemotherapy followed by the infusion of PBPC. The median number of days to recover neutrophils and platelets was 12 and 13, respectively. After a median follow-up of 28.7 months (range 17.2-43.4), five out of 11 patients who underwent PBPC transplantation are still in CR, five have died in first relapse and one is alive in CR after relapse treated with salvage therapy and second PBPC infusion. These results demonstrate that HiDAC consolidation chemotherapy followed by autologous PBPC transplantation is a feasible procedure with minimal toxicity. Randomized studies should be performed to evaluate whether this form of consolidation may produce a significant improvement in leukemia-free survival.

AB - Several trials have suggested that intensive post-remission therapy may prolong the duration of complete remission (CR) in acute myeloid leukemia (AML). The purpose of this study was to evaluate the feasibility and the efficacy of high-dose cytarabine (HiDAC) consolidation chemotherapy followed by high-dose therapy and autologous infusion of peripheral blood progenitor cells (PBPC) mobilized by G-CSF in adult patients with AML in first CR. Fifteen consecutive AML patients underwent HiDAC consolidation chemotherapy, used as a method of in vivo purging, followed by G-CSF for the purpose of autologous PBPC collection. Eleven patients collected a median of 6.9×10 8/kg peripheral blood mononuclear cells (MNC) (range 2.9-23) and a median of 6.67×10 6/kg CD34+ cells (range 1.8-33.5) with a median of two aphereses (range 1-3). Two patients did not mobilize and two obtained an inadequate number of progenitor cells. The 11 patients with adequate collections received myeloablative chemotherapy followed by the infusion of PBPC. The median number of days to recover neutrophils and platelets was 12 and 13, respectively. After a median follow-up of 28.7 months (range 17.2-43.4), five out of 11 patients who underwent PBPC transplantation are still in CR, five have died in first relapse and one is alive in CR after relapse treated with salvage therapy and second PBPC infusion. These results demonstrate that HiDAC consolidation chemotherapy followed by autologous PBPC transplantation is a feasible procedure with minimal toxicity. Randomized studies should be performed to evaluate whether this form of consolidation may produce a significant improvement in leukemia-free survival.

KW - AML

KW - Autologous transplantation

KW - Peripheral blood progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=0034981083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034981083&partnerID=8YFLogxK

U2 - 10.1007/s002770000277

DO - 10.1007/s002770000277

M3 - Article

C2 - 11446728

AN - SCOPUS:0034981083

VL - 80

SP - 267

EP - 271

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -